Market Overview:
The global α-blocker market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to the increasing prevalence of hypertension, rising geriatric population, and growing demand for α-blockers for the treatment of erectile dysfunction (ED). However, patent expirations of certain blockbuster drugs are expected to restrain the growth of this market during the forecast period. The global α-blocker market is segmented on the basis of type, application, and region. On the basis of type, it is divided into nonselective antagonists and selective antagonists. Nonselective antagonists are further classified into phenoxybenzamine hydrochloride (Dibenzyline®), prazosin hydrochloride (Minipress®), doxazosin mesylate (Cardura®), terazosin hydrochloride (Hytrin®), and alfuzosin hydrochloride (Uroxatralâ„¢). Selective antagonists are further classified into tamsulosin hydrochloride (Flomaxâ„¢) and silodosin capsules(Rapafloâ„¢).
Product Definition:
α-blockers are a type of drug that block the action of α receptors. They are used to treat conditions such as hypertension and benign prostatic hyperplasia.
Non-selective Antagonists:
Non-selective anticholinergic drugs block the acetylcholine receptor, which results in parasympathetic nerve inhibition. They are used to treat heart failure and certain types of glaucoma. The drug class includes atropine, scopolamine, benzquinamide and propantheline bromide among others.
Selective Antagonists:
A selective antagonist is a drug that binds to the α-blocker site on the human AHR (antihistamine, decongestant) and blocks some of the effects of histamine. They are used in combination with other drugs to treat allergic conditions such as hay fever and asthma.
Application Insights:
The hypertension segment dominated the global α-blocker market in 2017 and is expected to witness significant growth over the forecast period. Hypertension is a major public health concern as it leads to cardiovascular diseases, which are the leading cause of death globally. According to data published by WHO, more than 3 million deaths occur due to hypertension every year worldwide.
Non-selective antagonists such as acebutolol were found more effective in treating high blood pressure compared with other drugs present in the market such as captopril and lisinopril among others. This can be attributed to its ability of reducing blood pressure without causing any side effects or adverse reactions on organs like kidneys and liver among others.
Regional Analysis:
North America dominated the global market in 2017. High prevalence of hypertension, increasing cases of erectile dysfunction and rising awareness about sexual health are some factors responsible for its largest share. Moreover, presence of key players such as Pfizer Inc.; Merck & Co., Inc.; and Sanofi are also contributing towards the growth in this region.
Asia Pacific is expected to be the fastest-growing region over the forecast period owing to high unmet clinical needs coupled with rapidly improving healthcare infrastructure in emerging economies such as China and India. Furthermore, growing number of product launches by local companies will further boost revenue generation prospects for ‘global alpha blocker’ industry players operating within Asia Pacific region during 2018 - 2030 period.
Growth Factors:
- Increasing prevalence of hypertension and other cardiac disorders
- Growing geriatric population
- Rising awareness about the benefits of α-blockers
- Technological advancements in the field of α-blockers manufacturing 5. Availability of generic versions of branded α-blockers
Scope Of The Report
Report Attributes
Report Details
Report Title
α-blocker Market Research Report
By Type
Non-selective Antagonists, Selective Antagonists
By Application
Hypertension, Raynaud's Disease, Erectile Dysfunction
By Companies
Pfizer, Novartis, Merck, Astra Zeneca, Jhonson and Johnson, Eli Lilly, Sanofi, Bristol-Myers Squibb, Bayer, GSK, Pfizer
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
187
Number of Tables & Figures
131
Customization Available
Yes, the report can be customized as per your need.
Global α-blocker Market Report Segments:
The global α-blocker market is segmented on the basis of:
Types
Non-selective Antagonists, Selective Antagonists
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hypertension, Raynaud's Disease, Erectile Dysfunction
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Novartis
- Merck
- Astra Zeneca
- Jhonson and Johnson
- Eli Lilly
- Sanofi
- Bristol-Myers Squibb
- Bayer
- GSK
- Pfizer
Highlights of The α-blocker Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Non-selective Antagonists
- Selective Antagonists
- By Application:
- Hypertension
- Raynaud's Disease
- Erectile Dysfunction
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the α-blocker Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
An α-blocker is a medication that blocks the action of α-amylase, an enzyme that helps digest food. This can lead to reduced absorption of nutrients from food and may increase the risk for stomach ulcers.
Some of the key players operating in the î±-blocker market are Pfizer, Novartis, Merck, Astra Zeneca, Jhonson and Johnson, Eli Lilly, Sanofi, Bristol-Myers Squibb, Bayer, GSK, Pfizer.
The ±-blocker market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 α-blocker Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 α-blocker Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 α-blocker Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the α-blocker Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global α-blocker Market Size & Forecast, 2020-2028
4.5.1 α-blocker Market Size and Y-o-Y Growth
4.5.2 α-blocker Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Non-selective Antagonists
5.2.2 Selective Antagonists
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hypertension
6.2.2 Raynaud's Disease
6.2.3 Erectile Dysfunction
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global α-blocker Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 α-blocker Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Non-selective Antagonists
9.6.2 Selective Antagonists
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hypertension
9.10.2 Raynaud's Disease
9.10.3 Erectile Dysfunction
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Non-selective Antagonists
10.6.2 Selective Antagonists
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hypertension
10.10.2 Raynaud's Disease
10.10.3 Erectile Dysfunction
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Non-selective Antagonists
11.6.2 Selective Antagonists
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hypertension
11.10.2 Raynaud's Disease
11.10.3 Erectile Dysfunction
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Non-selective Antagonists
12.6.2 Selective Antagonists
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hypertension
12.10.2 Raynaud's Disease
12.10.3 Erectile Dysfunction
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Non-selective Antagonists
13.6.2 Selective Antagonists
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hypertension
13.10.2 Raynaud's Disease
13.10.3 Erectile Dysfunction
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 α-blocker Market: Competitive Dashboard
14.2 Global α-blocker Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 Novartis
14.3.3 Merck
14.3.4 Astra Zeneca
14.3.5 Jhonson and Johnson
14.3.6 Eli Lilly
14.3.7 Sanofi
14.3.8 Bristol-Myers Squibb
14.3.9 Bayer
14.3.10 GSK
14.3.11 Pfizer
